Lawsuit filed for Investors who lost money with shares of LifeMD, Inc. (NASDAQ: LFMD)

An investor, who purchased shares of LifeMD, Inc. (NASDAQ: LFMD), filed a lawsuit over alleged violations of Federal Securities Laws by LifeMD, Inc. in connection with certain allegedly false and misleading statements.

Investors who purchased shares of LifeMD, Inc. (NASDAQ: LFMD) have certain options and for certain investors are short and strict deadlines running. Deadline: October 27, 2025. NASDAQ: LFMD investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

New York based LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. LifeMD, Inc. (NASDAQ: LFMD) reported that its annual Total Revenue rose from $152.54 million in 2023 to $212.45 million in 2024, and that its Net Loss declined from $20.59 million in 2023 to $18.88 million in 2024.

On August 5, 2025, after the market closed, LifeMD, Inc reported its financial results for the second quarter of 2025. In this announcement, LifeMD announced revised guidance. Among other metrics, LifeMD stated that it was expecting total revenue in the range of $250 to $255 million, compared with previous guidance of $268 to $275 million.

Shares of LifeMD, Inc. (NASDAQ: LFMD) declined from $15.84 per share on June 23, 2025, to as low as $5.95 per share on August 20, 2025.

The plaintiff claims that between May 7, 2025 and August 5, 2025, the defendants made materially false and/or misleading statements and/or failed to disclose that the Defendants materially overstated LifeMD's competitive position, that the Defendants were reckless in raising LifeMD's 2025 guidance, considering that they had not properly accounted for rising customer acquisition costs in LifeMD's RexMD segment, as well as for customer acquisition costs related to the sale of drugs designed to treat obesity, including Wegovy and Zepbound, and that as a result, defendants' statements about LifeMD's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times.

Those who purchased shares of LifeMD, Inc. (NASDAQ: LFMD) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.